Improvement of microangiopathy after haematopoietic stem cell transplantation in systemic sclerosis.

OBJECTIVES Haematopoietic stem cell transplantation (HSCT) is a treatment option for patients with severe systemic sclerosis (SSc), but the efficacy of the procedure in remodelling the nailfold microvascular array is largely unknown. Therefore, this study aimed to evaluate the effect of HSCT on microangiopathy assessed through nailfold capillaroscopy (NC) and to compare the results with findings in patients receiving conventional immunosuppression. METHODS We included SSc patients with severe SSc and whose pre- and post-treatment NC images were available. Findings in patients treated with HSCT were compared with patients not treated with HSCT. Images were scored by two independent observers blinded for clinical data and treatment history. Capillary pattern was determined and semiquantitative scores from 0 (no changes) to 3 (>66% alterations per millimetre) were used to quantify the degree of specific microvascular characteristics. Changes in severity of microangiopathy between baseline and post-treatment were compared between groups. RESULTS Images of 18 HSCT patients and 21 controls were scored. From baseline to follow-up, 33% of HSCT patients showed improvement from scleroderma pattern to normal NC, compared to 6% of controls (p=0.15). Pre- to post-treatment differences in semiquantitative scores showed significant improvement in HSCT patients compared to controls regarding capillary loss (-0.5 vs. 0.0, p<0.05) and disorganisation (-0.8 vs. 0.0, p<0.05). CONCLUSIONS The degree of microangiopathy improved significantly in severe SSc patients treated with HSCT compared with patients receiving conventional immunosuppressive therapy.

[1]  D. Covas,et al.  Autologous hematopoietic stem cell transplantation modifies specific aspects of systemic sclerosis-related microvasculopathy , 2022, Therapeutic advances in musculoskeletal disease.

[2]  D. Furst,et al.  Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS). , 2021, The Lancet. Rheumatology.

[3]  A. Della Rossa,et al.  One year in review 2021: systemic sclerosis. , 2021, Clinical and experimental rheumatology.

[4]  J. D. de Vries-Bouwstra,et al.  Smoking and systemic sclerosis: influence on microangiopathy and expression of anti-topoisomerase I antibodies in a monocentric cohort. , 2020, Clinical and experimental rheumatology.

[5]  J. D. de Vries-Bouwstra,et al.  Sex hormones and sex hormone-targeting therapies in systemic sclerosis: A systematic literature review. , 2020, Seminars in arthritis and rheumatism.

[6]  A. Iagnocco,et al.  Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis. , 2020, Autoimmunity reviews.

[7]  M. Cutolo,et al.  Progression of nailfold capillaroscopic patterns and correlation with organ involvement in systemic sclerosis: a 12 year study. , 2019, Rheumatology.

[8]  J. D. de Vries-Bouwstra,et al.  Cumulative endogenous estrogen exposure is not associated with severity of peripheral microangiopathy in patients with systemic sclerosis. , 2019, Clinical and experimental rheumatology.

[9]  S. Blaise,et al.  Correlation between capillaroscopic classifications and severity in systemic sclerosis: results from SCLEROCAP study at inclusion. , 2019, Clinical and experimental rheumatology.

[10]  N. Del Papa,et al.  The Role of Endothelial Progenitors in the Repair of Vascular Damage in Systemic Sclerosis , 2018, Front. Immunol..

[11]  I. Marie,et al.  Environmental risk factors of systemic sclerosis , 2015, Seminars in Immunopathology.

[12]  B. Griffiths,et al.  Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. , 2014, JAMA.

[13]  C. Kayser,et al.  Nailfold capillaroscopy abnormalities as predictors of mortality in patients with systemic sclerosis. , 2013, Clinical and experimental rheumatology.

[14]  M. Cutolo,et al.  Timing of transition between capillaroscopic patterns in systemic sclerosis. , 2012, Arthritis and rheumatism.

[15]  D. Wuttge,et al.  Assessment of capillary density in systemic sclerosis with three different capillaroscopic methods. , 2012, Clinical and experimental rheumatology.

[16]  C. Thalhammer,et al.  Rapid improvement of nailfold capillaroscopy after intense immunosuppression for systemic sclerosis and mixed connective tissue disease , 2008, Annals of the rheumatic diseases.

[17]  M. Conforti,et al.  Autologous stem cell transplantation improves microcirculation in systemic sclerosis , 2008, Annals of the rheumatic diseases.

[18]  Stephen M. Schwartz,et al.  Capillary Regeneration in Scleroderma: Stem Cell Therapy Reverses Phenotype? , 2008, PloS one.

[19]  James F. Fries,et al.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. , 1980, Arthritis and rheumatism.

[20]  Hugh Gordon,et al.  Scleroderma , 1937 .

[21]  T. Medsger,et al.  Assessment of disease severity and prognosis. , 2003, Clinical and experimental rheumatology.

[22]  A Sulli,et al.  Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. , 2000, The Journal of rheumatology.